RT @MariaSolAndres1: Last week I got a call from the @royalmarsdenNHS to review a patient with #CRS and fast AF... I had to google what CRS…
RT @MariaSolAndres1: Last week I got a call from the @royalmarsdenNHS to review a patient with #CRS and fast AF... I had to google what CRS…
RT @MariaSolAndres1: Last week I got a call from the @royalmarsdenNHS to review a patient with #CRS and fast AF... I had to google what CRS…
Last week I got a call from the @royalmarsdenNHS to review a patient with #CRS and fast AF... I had to google what CRS and #tocilizumab were... today it appears on @JACCJournals’ front page... this is how fast #CardioOncology is growing.
RT @JACCJournals: Should we measure troponins in #cancer patients treated with Chimeric antigen receptor T-cells? New #JACC paper suggests…
RT @JACCJournals: Should we measure troponins in #cancer patients treated with Chimeric antigen receptor T-cells? New #JACC paper suggests…
Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T) | JACC: Journal of the American College of Cardiology, CAR-T therapy next big thing but it’s cardiovascular effects even bigger thing #JACC #CART https://t.co/ZUfH64
RT @JACCJournals: Should we measure troponins in #cancer patients treated with Chimeric antigen receptor T-cells? New #JACC paper suggests…
RT @JACCJournals: Should we measure troponins in #cancer patients treated with Chimeric antigen receptor T-cells? New #JACC paper suggests…
RT @JACCJournals: Should we measure troponins in #cancer patients treated with Chimeric antigen receptor T-cells? New #JACC paper suggests…
RT @JACCJournals: Should we measure troponins in #cancer patients treated with Chimeric antigen receptor T-cells? New #JACC paper suggests…
RT @JACCJournals: Should we measure troponins in #cancer patients treated with Chimeric antigen receptor T-cells? New #JACC paper suggests…
RT @JACCJournals: Should we measure troponins in #cancer patients treated with Chimeric antigen receptor T-cells? New #JACC paper suggests…
RT @JACCJournals: Should we measure troponins in #cancer patients treated with Chimeric antigen receptor T-cells? New #JACC paper suggests…
RT @NYAMNYC: Congratulations to Dr. S. Saad Mahmood of @nyphospital/@WeillCornell, NYAM's 2019-20 Glorney-Raisbeck Fellow in #Cardiovascula…
Congratulations to Dr. S. Saad Mahmood of @nyphospital/@WeillCornell, NYAM's 2019-20 Glorney-Raisbeck Fellow in #Cardiovascular Diseases, on his new research published in @JACCJournals. We're proud to support his important research in cardio-#oncology! #Ca
RT @avirupguha: Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T) https://t.co/KUajR8w0Wn @JACCJour…
RT @JACCJournals: Should we measure troponins in #cancer patients treated with Chimeric antigen receptor T-cells? New #JACC paper suggests…
RT @MGHHeartHealth: The very latest from our Dr. Tom Neilan and the #MGH Cardio-Oncology Program: https://t.co/uhguw4f5Eq
RT @JACCJournals: Should we measure troponins in #cancer patients treated with Chimeric antigen receptor T-cells? New #JACC paper suggests…
RT @MGHHeartHealth: The very latest from our Dr. Tom Neilan and the #MGH Cardio-Oncology Program: https://t.co/uhguw4f5Eq
The very latest from our Dr. Tom Neilan and the #MGH Cardio-Oncology Program:
RT @JACCJournals: Should we measure troponins in #cancer patients treated with Chimeric antigen receptor T-cells? New #JACC paper suggests…
RT @JACCJournals: Should we measure troponins in #cancer patients treated with Chimeric antigen receptor T-cells? New #JACC paper suggests…
RT @JACCJournals: Should we measure troponins in #cancer patients treated with Chimeric antigen receptor T-cells? New #JACC paper suggests…
RT @JACCJournals: Should we measure troponins in #cancer patients treated with Chimeric antigen receptor T-cells? New #JACC paper suggests…
RT @JACCJournals: Should we measure troponins in #cancer patients treated with Chimeric antigen receptor T-cells? New #JACC paper suggests…
Should we measure troponins in #cancer patients treated with Chimeric antigen receptor T-cells? New #JACC paper suggests this may help determine which patients are at highest risk for CV events post-treatment. https://t.co/94mD6e86DJ @MGHHeartHealth https:
RT @saadhealth: Happy to share: early use of #tocilizumab after #cytokine #release #syndrome in #CAR-T cell recipients associated w/ less #…
RT @pedschwartzmann: @DrRenatoCunha ! #cardioOncology together with the new improvements in the field! Count on us! https://t.co/sIVlAAvVyy
RT @saadhealth: Happy to share: early use of #tocilizumab after #cytokine #release #syndrome in #CAR-T cell recipients associated w/ less #…
RT @arjunkg: Great work to further our understanding of #cardiotoxicity with the newest immune therapy - #CARTcells @drclaireroddie @avirup…
More evidence that multiple forms of chemotherapy can increase risk of developing new onset heart failure or cause CV death! @JACCJournals https://t.co/utKQW5t8GA
RT @saadhealth: Happy to share: early use of #tocilizumab after #cytokine #release #syndrome in #CAR-T cell recipients associated w/ less #…
RT @arjunkg: Great work to further our understanding of #cardiotoxicity with the newest immune therapy - #CARTcells @drclaireroddie @avirup…
Excellent work @saadhealth @Dr_Mike_Fradley and Tom Neilan.
RT @saadhealth: Happy to share: early use of #tocilizumab after #cytokine #release #syndrome in #CAR-T cell recipients associated w/ less #…
RT @saadhealth: Happy to share: early use of #tocilizumab after #cytokine #release #syndrome in #CAR-T cell recipients associated w/ less #…
Congrats to all authors for this very important study!
RT @pedschwartzmann: @DrRenatoCunha ! #cardioOncology together with the new improvements in the field! Count on us! https://t.co/sIVlAAvVyy
@DrRenatoCunha ! #cardioOncology together with the new improvements in the field! Count on us!
RT @avirupguha: Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T) https://t.co/KUajR8w0Wn @JACCJour…
RT @saadhealth: Happy to share: early use of #tocilizumab after #cytokine #release #syndrome in #CAR-T cell recipients associated w/ less #…
Interesting observational study by @raza_alvi786 et al on #cardiovascular events in patients treated with #CART cell therapy @MJFzeta @saadhealth #lymsm #oncology https://t.co/dCqEOhmKuo
RT @saadhealth: Happy to share: early use of #tocilizumab after #cytokine #release #syndrome in #CAR-T cell recipients associated w/ less #…
Cardiovascular Events Among Adults Treated With Chimeric Antigen Recep... https://t.co/6jkaPWkKxr
RT @saadhealth: Happy to share: early use of #tocilizumab after #cytokine #release #syndrome in #CAR-T cell recipients associated w/ less #…
RT @avirupguha: Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T) https://t.co/KUajR8w0Wn @JACCJour…
RT @saadhealth: Happy to share: early use of #tocilizumab after #cytokine #release #syndrome in #CAR-T cell recipients associated w/ less #…
RT @arjunkg: Great work to further our understanding of #cardiotoxicity with the newest immune therapy - #CARTcells @drclaireroddie @avirup…
RT @saadhealth: Happy to share: early use of #tocilizumab after #cytokine #release #syndrome in #CAR-T cell recipients associated w/ less #…
RT @arjunkg: Great work to further our understanding of #cardiotoxicity with the newest immune therapy - #CARTcells @drclaireroddie @avirup…
RT @saadhealth: Happy to share: early use of #tocilizumab after #cytokine #release #syndrome in #CAR-T cell recipients associated w/ less #…
RT @saadhealth: Happy to share: early use of #tocilizumab after #cytokine #release #syndrome in #CAR-T cell recipients associated w/ less #…
RT @arjunkg: Great work to further our understanding of #cardiotoxicity with the newest immune therapy - #CARTcells @drclaireroddie @avirup…
RT @arjunkg: Great work to further our understanding of #cardiotoxicity with the newest immune therapy - #CARTcells @drclaireroddie @avirup…
Great work to further our understanding of #cardiotoxicity with the newest immune therapy - #CARTcells @drclaireroddie @avirupguha @dhdchen @DocJMW @ProfBMT @DanielSierraMD8 @OSUCardioOnc @onco_cardiology @drbrowncares #CardioOnc #CardioOncology
Interesting. CAR-T and CV events. Not uncommon at the J service.
RT @saadhealth: Happy to share: early use of #tocilizumab after #cytokine #release #syndrome in #CAR-T cell recipients associated w/ less #…
RT @saadhealth: Happy to share: early use of #tocilizumab after #cytokine #release #syndrome in #CAR-T cell recipients associated w/ less #…
RT @saadhealth: Happy to share: early use of #tocilizumab after #cytokine #release #syndrome in #CAR-T cell recipients associated w/ less #…
Happy to share: early use of #tocilizumab after #cytokine #release #syndrome in #CAR-T cell recipients associated w/ less #cardiovascular events. Grateful to @NYAMNYC for funding our work. https://t.co/LmYXVLk1Dl @WeillCornell @nyphospital @sloan_kettering
トシリズマブ投与12時間遅延に伴い、CVイベントリスクは1.7倍に。 https://t.co/oqiAAu4Bdg
RT @avirupguha: Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T) https://t.co/KUajR8w0Wn @JACCJour…
RT @avirupguha: Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T) https://t.co/KUajR8w0Wn @JACCJour…
Thank you to @Dr_Mike_Fradley and collaborators at MGH for this opportunity!!
RT @avirupguha: Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T) https://t.co/KUajR8w0Wn @JACCJour…
RT @avirupguha: Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T) https://t.co/KUajR8w0Wn @JACCJour…
RT @zsofidrobni: So happy to be part of this project!! 🥳 #cardioonc #JACC #MGH @ZhanglilyA #Neilan https://t.co/MjkWEBHFV2
So happy to be part of this project!! 🥳 #cardioonc #JACC #MGH @ZhanglilyA #Neilan
RT @avirupguha: Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T) https://t.co/KUajR8w0Wn @JACCJour…
RT @avirupguha: Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T) https://t.co/KUajR8w0Wn @JACCJour…
RT @avirupguha: Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T) https://t.co/KUajR8w0Wn @JACCJour…
Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T) https://t.co/KUajR8w0Wn @JACCJournals great #cardioonc article by a highly collaborative group @Dr_Mike_Fradley @saadhealth